CRBU vs. INO

Last updated Aug 1, 2026

CRBU (Caribou Biosciences, Inc.) and INO (Inovio Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CRBU returned -38.20%/yr vs -63.24%/yr for INO. Their 0.46 correlation means their historical movements had little consistent relationship.

Performance

CRBU vs. INO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Caribou Biosciences, Inc. (CRBU) and Inovio Pharmaceuticals, Inc. (INO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CRBU achieves a -8.18% return, which is significantly higher than INO's -61.09% return.

CRBU

• 1D: -3.31%
• 1M: -19.78%
• 6M: 3.55%
• YTD: -8.18%
• 1Y: -25.13%
• 3Y*: -41.55%
• 5Y*: -38.20%
• 10Y*: —
• ALL TIME*: -39.13%

INO

• 1D: 3.20%
• 1M: -44.51%
• 6M: -58.47%
• YTD: -61.09%
• 1Y: -52.66%
• 3Y*: -51.59%
• 5Y*: -63.24%
• 10Y*: -40.51%
• ALL TIME*: -22.28%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
CRBU Caribou Biosciences, Inc.	$1.81M	$3.07M	$3.70M
INO Inovio Pharmaceuticals, Inc.	$4.50M	$2.97M	$3.39M

CRBU vs. INO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
CRBU Caribou Biosciences, Inc.	-8.18%	0.00%	-72.25%	-8.76%	-58.38%	-14.50%
INO Inovio Pharmaceuticals, Inc.	-61.09%	-4.92%	-70.10%	-67.31%	-68.74%	-42.25%

Correlation

The correlation between CRBU and INO is 0.37, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.37
Correlation (3Y) Balances recent behavior with more history.	0.42
Correlation (5Y) Shows whether the relationship held over a longer period.	0.46
Correlation (All Time) Calculated using the full available price history since Jul 23, 2021	0.46

Fundamentals

Market Cap CRBU : $144.80M INO : $36.28M
EPS CRBU : -$1.41 INO : -$48.88
PB Ratio CRBU : 1.37 INO : 0.08
Total Revenue (TTM) CRBU : $8.81M INO : $0.00
Gross Profit (TTM) CRBU : $7.49M INO : -$1.50M
EBITDA (TTM) CRBU : -$115.23M INO : -$22.01B

Return for Risk

CRBU vs. INO — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

CRBU

CRBU Risk / Return Rank: 28
CRBU Sharpe Ratio Rank: 27
CRBU Sortino Ratio Rank: 30
CRBU Omega Ratio Rank: 31
CRBU Calmar Ratio Rank: 24
CRBU Martin Ratio Rank: 26

INO

INO Risk / Return Rank: 18
INO Sharpe Ratio Rank: 17
INO Sortino Ratio Rank: 22
INO Omega Ratio Rank: 20
INO Calmar Ratio Rank: 18
INO Martin Ratio Rank: 14

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

CRBU vs. INO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Caribou Biosciences, Inc. (CRBU) and Inovio Pharmaceuticals, Inc. (INO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CRBU	INO	Difference
Sharpe ratio: Return per unit of total volatility	-0.38	-0.60	+0.23
Sortino ratio: Return per unit of downside risk	-0.11	-0.47	+0.35
Omega ratio: Gain probability vs. loss probability	0.99	0.93	+0.06
Calmar ratio: Return relative to maximum drawdown	-0.55	-0.68	+0.13
Martin ratio: Return relative to average drawdown	-0.89	-1.23	+0.34

CRBU vs. INO - Sharpe Ratio Comparison

The current CRBU Sharpe Ratio is -0.38, which is higher than the INO Sharpe Ratio of -0.60. The chart below compares the historical Sharpe Ratios of CRBU and INO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

CRBU vs. INO - Drawdown Comparison

The maximum CRBU drawdown since its inception was -97.58%, roughly equal to the maximum INO drawdown of -99.97%. Use the drawdown chart below to compare losses from any high point for CRBU and INO.

Drawdown Indicators

	CRBU	INO	Difference
Max Drawdown Largest peak-to-trough decline	-97.58%	-99.97%	+2.39%
Max Drawdown (1Y) Largest decline over 1 year	-51.06%	-77.14%	+26.08%
Max Drawdown (3Y) Largest decline over 3 years	-91.12%	-95.27%	+4.15%
Max Drawdown (5Y) Largest decline over 5 years	-97.58%	-99.44%	+1.86%
Max Drawdown (10Y) Largest decline over 10 years	—	-99.83%	—
Current Drawdown Current decline from peak	-95.18%	-99.97%	+4.79%
Average Drawdown Average peak-to-trough decline	-79.71%	-92.38%	+12.67%
Ulcer Index Depth and duration of drawdowns from previous peaks	31.64%	42.55%	-10.91%

Volatility

CRBU vs. INO - Volatility Comparison

The current volatility for Caribou Biosciences, Inc. (CRBU) is 13.75%, while Inovio Pharmaceuticals, Inc. (INO) has a volatility of 47.66%. This indicates that CRBU experiences smaller price fluctuations and is considered to be less risky than INO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRBU	INO	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.75%	47.66%	-33.91%
Volatility (6M) Calculated over the trailing 6-month period	48.91%	73.50%	-24.59%
Volatility (1Y) Calculated over the trailing 1-year period	74.25%	86.75%	-12.50%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	86.14%	87.21%	-1.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	86.04%	93.96%	-7.92%

Dividends

CRBU vs. INO - Dividend Comparison

Neither CRBU nor INO has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both CRBU and INO in my portfolio?

CRBU and INO have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CRBU or INO?

INO has higher volatility (47.66%) compared to CRBU (13.75%). In terms of maximum drawdown, CRBU dropped -97.58% vs INO's -99.97%.

Which has better risk-adjusted returns?

CRBU currently has the higher Sharpe Ratio (-0.38 vs -0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.